Status:
ACTIVE_NOT_RECRUITING
Aerobic Exercise is Cardio-protective in Hemato-oncological Disease and New-onset Chemotherapy
Lead Sponsor:
Lucía Florio
Conditions:
Cardiotoxicity
Systolic Dysfunction
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Oncological diseases are the main cause of death in developed countries and also in Uruguay. Advances in therapeutics have made possible to aspire to cure and in other cases long-term remission with a...
Detailed Description
Hypothesis: an aerobic physical exercise program for at least 3 months, in subjects with hemato-oncological diseases that initiate chemotherapy, is effective in preventing systolic dysfunction of the ...
Eligibility Criteria
Inclusion
- Between 18 and 75 years old
- New-onset chemotherapy
- Lymphoma (Hodgkin or non-Hodgkin).
Exclusion
- Inability or contraindication to moderate physical activity due to orthopedic cause or general disease (excluding oncological).
- Hemato-oncological pathology different from lymphomas.
- Lymphomas not treated with anthracyclines
- Non-sinus rhythm.
- Poor echocardiographic window (inability to assess longitudinal strain in more than 4 segments).
- Physically active subjects (practice aerobic exercise at least 30 minutes, 3 times / week, 3 previous months).
Key Trial Info
Start Date :
March 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04476576
Start Date
March 2 2021
End Date
June 30 2025
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Cardiovascular Universitario-Hospital de Clínicas -FMED- UdelaR
Montevideo, Uruguay, 11600